Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema

Basit Öğe Kaydı
dc.contributor.authorOzturk, Banu Turgut
dc.contributor.authorKerimoglu, Hurkan
dc.contributor.authorAdam, Mehmet
dc.contributor.authorGunduz, Kemal
dc.contributor.authorOkudan, Suleyman
dc.date.accessioned2020-03-26T18:14:47Z
dc.date.available2020-03-26T18:14:47Z
dc.date.issued2011
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractPurpose: To evaluate the effect of glucose regulation on intravitreal ranibizumab injection for clinically significant diabetic macular edema (DME). Methods: This retrospective study enrolled 65 eyes of 65 patients with persistent DME treated with intravitreal ranibizumab injection. The main outcome measures were the change in best corrected visual acuity (BCVA), the central subfield macular thickness (CSMT) recorded with optical coherence tomography (OCT), and its correlation with the serum hemoglobin A(1c) values (HbA(1c)). Results: The study included 24 (36.9%) female and 41(63.1%) male patients with a mean age of 58.90 +/- 9.45 years. The mean HbA(1c) of the enrolled patients was 8.25 +/- 1.74% (range 5.7-12.7%). The median value of BCVA at baseline examination was 20/80 (52 letters), and the median CSMT was 468 pm (range 255-964 mu m). In the final control after 4-6 weeks following injection, the median value of BCVA increased to 20/50 (59.50 letters) and the median CSMT decreased to 310 pin (range 129-652 mu m). This change in BCVA and macular thickness was found to be significant (P<.001 for both). There was no correlation between BCVA and the change in macular thickness (coefficient=0.04, P=.78). The serum HbA(1c) values were found to be negatively correlated with the change in CSMT (coefficient=-0.50, P<.001). Conclusions: The results of intravitreal ranibizumab injection for DME demonstrated a beneficial effect on visual acuity and a decrease in CSMT which is inversely correlated with the serum HbA(1c), level. (C) 2011 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.jdiacomp.2010.09.006en_US
dc.identifier.endpage302en_US
dc.identifier.issn1056-8727en_US
dc.identifier.issn1873-460Xen_US
dc.identifier.issue5en_US
dc.identifier.pmid21075650en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage298en_US
dc.identifier.urihttps://dx.doi.org/10.1016/j.jdiacomp.2010.09.006
dc.identifier.urihttps://hdl.handle.net/20.500.12395/26525
dc.identifier.volume25en_US
dc.identifier.wosWOS:000295193900004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherELSEVIER SCIENCE INCen_US
dc.relation.ispartofJOURNAL OF DIABETES AND ITS COMPLICATIONSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectRanibizumaben_US
dc.subjectDiabetic macular edemaen_US
dc.subjectGlucose regulationen_US
dc.subjectMacular thicknessen_US
dc.titleGlucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edemaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu